Team

image of team members

meet Our Team

image of team member

Dr. Madhumita Basu

Principal Scientist, Target Discovery
image of team member

Dr. Perry Bickel

Scientific Advisory Board
image of team member

Dr. Benjamin T. Bikman

Scientific Advisory Board
image of team member

Dr. Aaron Glieberman

Director, Platform Development
image of team member

Pareesha Haresh

Research & Development Technician
image of team member

Dr. Prakash Jagtap

Director, Medicinal Chemistry
image of team member

Timothy Jones

Board of Directors
image of team member

Sunday Oworah

Operations Manager
image of team member

Dr. Quinn P. Peterson

Scientific Advisory Board
image of team member

Dr. Ben Pope

Chief Executive Officer, Founder
image of team member

Nicole Rinaldi

Research & Development Engineer
image of team member

Todd Spalding

Board of Directors
image of team member

Dr. Fatima Stanford

Scientific Advisory Board
image of team member

Gianna Tamilio

Data Science Intern
image of team member

Dr. Jonathan Williams

Scientific Advisory Board
image of team member

Andreas Windemuth

Director, Technology
image of team member

Dr Todd Zion

Scientific Advisory Board

Recent News

Join the excitement! Explore the latest news and vibrant events at MelliCell!

See all news picture of recent news
picture of recent news
Jul 14, 2025

MelliCell welcomes Dr. Davide Ruggero to Scientific Advisory Board

MelliCell, a biotech company pioneering fat-targeted therapeutics for obesity and associated chronic disease, is proud to announce that Dr. Davide Ruggero, PhD, has joined its scientific advisory board. This addition reinforces MelliCell’s commitment to scientific excellence and innovation to improve human health.

Dr. Ruggero is the Goldberg-Benioff and Hellen Diller Family Endowed Chair, American Cancer Society Research Professor, and Professor of Urology and Cellular & Molecular Pharmacology at the University of California, San Francisco. He is internationally recognized for his groundbreaking research on how impairments in the control of mRNA translation and protein synthesis contribute to human disease. His laboratory’s pioneering work in translational control has opened new biological pathways and has laid the foundation for developing next-generation therapeutics that modulate the cellular proteome at the post-genomic level.

"Dr. Ruggero’s longstanding expertise in how the pathways that control translation steer key biological processes and intersect with human metabolism is a perfect complement to MelliCell’s mission and progress to date," said Dr. Ben Pope, CEO of MelliCell. "His discoveries have laid a groundwork that will play a critical role in guiding the development of our pipeline and platform technology."

Dr. Ruggero has been the recipient of numerous prestigious awards including the Memorial Sloan-Kettering Outstanding Research Fellow Award, the V-Scholar Foundation’s Award for Cancer Research, the AACR Gertrude B. Elion Research Award, the Leukemia & Lymphoma Society Scholar Award, the Outstanding Investigator Award (R35) from the National Institutes of Health, and the prestigious American Cancer Society Professor Award. He is also the inventor of multiple clinical-stage drug candidates and the founding scientist of Effector Therapeutics (NASDAQ: EFTR), a biotech company that pioneered therapeutics targeting human protein translation. His leadership will help drive MelliCell’s mission forward as MelliCell prepares its first development candidates for clinical trials.

"I’m excited to join MelliCell at a time when a deeper understanding of adipocyte biology is reshaping our view of chronic diseases," said Dr. Ruggero. "MelliCell’s innovative technology is uncovering novel therapeutic strategies to reverse the progression of obesity and over 200 associated complications including cancer. MelliCell is getting at the root of chronic disease and I’m beyond excited to support the vision."

About MelliCell:

MelliCell Inc. is a biotechnology company redefining how fat cells are studied and targeted in chronic disease. By developing models that grow mature human adipocytes with physiological relevance, MelliCell is unlocking new insights into how fat cells contribute to obesity, diabetes, cancer, and other metabolic conditions. Through its proprietary M3 technology, MelliCell is building a foundation for the next generation of therapies aimed at the cellular root of metabolic dysfunction.

For more information, please visit 

www.mellicell.com

Read More

Events

picture of event
picture of event
picture of event
picture of event
picture of event